Hefei Shengpu Pharmaceutical

Hefei Shengpu Pharmaceutical is a private Chinese drug discovery company founded in 2024 in Hefei, Anhui. Publicly available descriptions indicate that the company focuses on the research, development, and industrialization of small-molecule innovative drugs and high-end formulations. Recent patent-related reporting links the company to KRAS mutant inhibitor programs for oncology, suggesting an early-stage precision oncology focus. Corporate registry data show the company is active and privately held, and financing disclosures indicate it raised venture funding from Jingsheng Capital in early 2026. Overall, Shengpu appears to be a newly formed, discovery-stage small-molecule pharma company with limited public disclosure beyond corporate registration, financing, and patent activity.